Understanding Benzo Metabolism: A Comprehensive Guide for Healthcare Professionals

Benzodiazepines are a class of medications widely recognized for their therapeutic effects on the central nervous system (CNS). These drugs, including well-known examples like alprazolam, diazepam, and lorazepam, are essential in clinical practice for managing a range of conditions from anxiety and insomnia to seizures and alcohol withdrawal. Their efficacy and widespread use necessitate a deep understanding of their pharmacology, particularly Benzo Metabolism, to ensure patient safety and optimize treatment outcomes.

This article delves into the critical aspects of benzodiazepines, focusing on their indications, mechanism of action, administration, adverse effects, contraindications, and importantly, their metabolic pathways. A thorough grasp of benzo metabolism is crucial for healthcare professionals to personalize treatment plans, predict drug interactions, and manage patients with varying physiological conditions, such as hepatic or renal impairment. This guide aims to provide an enhanced understanding of benzodiazepines, emphasizing the significance of benzo metabolism in clinical decision-making.

Objectives:

• Differentiate between various benzodiazepines based on their pharmacokinetic profiles, with a focus on benzo metabolism.
• Explain the metabolic pathways of common benzodiazepines and the factors influencing benzo metabolism.
• Apply knowledge of benzo metabolism to personalize benzodiazepine treatment, considering patient-specific factors like age and organ function.
• Recognize the clinical implications of benzo metabolism in drug interactions and adverse effect profiles.
• Emphasize the role of interprofessional collaboration in optimizing benzodiazepine therapy and patient care.

Access free multiple choice questions on this topic.

Indications for Benzodiazepine Use

Benzodiazepines are prescribed for a diverse array of conditions due to their potent effects on the CNS. These medications primarily target benzodiazepine receptors, playing a vital role in managing various neurological and psychiatric disorders. Their ability to quickly halt seizure activity is particularly critical, especially in emergency settings. Common FDA-approved indications include managing insomnia, acute status epilepticus, inducing amnesia, and treating agitation, anxiety, spastic conditions, and seizure disorders. Beyond these, benzodiazepines are also frequently used off-label in psychiatry to address conditions such as Tourette syndrome, delirium, delirium tremens, various sleep disorders, and medication-induced movement disorders like tremors, tics, tardive dyskinesia, and chorea. [1, 2]

FDA-Approved Indications

Several benzodiazepines have received FDA approval for specific indications, primarily focusing on anxiety, seizure management, and alcohol withdrawal:

• Chlordiazepoxide: Primarily indicated for managing alcohol withdrawal syndrome. [4]

• Clonazepam: Approved for treating panic disorder and agoraphobia. [3] It is also effective in treating myoclonic and absence seizures. [6]

• Diazepam: Used in the management of alcohol withdrawal. [7] Rectal diazepam is also indicated for febrile seizures. [8]

• Flurazepam: Indicated for the treatment of insomnia. [9]

• Midazolam: Used for convulsive status epilepticus and procedural sedation. Midazolam is also utilized for sedation in mechanically ventilated patients in intensive care units. [11]

• Quazepam: Primarily indicated for chronic insomnia in adults. [13]

• Triazolam: Primarily indicated for sleep-onset insomnia.

• Remimazolam: Approved by the FDA in 2020 for short-term procedural sedation in adults. [14]

Image: Chemical structure of Diazepam, a common benzodiazepine, highlighting its complex ring structure relevant to its metabolism.

Mechanism of Action: How Benzodiazepines Work

Benzodiazepines exert their therapeutic effects by interacting with benzodiazepine receptors in the CNS. These receptors are integral components of the gamma-aminobutyric acid type A (GABA-A) receptor, a complex protein structure that forms a chloride channel. The GABA-A receptor consists of five transmembrane subunits: two alpha, two beta, and one gamma. GABA, an inhibitory neurotransmitter, binds to receptor sites formed by the extracellular portions of the alpha and beta subunits. Benzodiazepines, on the other hand, bind to a separate site located at the interface of the alpha and gamma subunits.

Upon benzodiazepine binding, a conformational change occurs in the central pore of the GABA-A receptor, facilitating the influx of chloride ions into the neuron. This chloride influx leads to hyperpolarization of the neuron, resulting in CNS depression. [15] Crucially, benzodiazepines enhance the efficiency of GABA by increasing the frequency of GABA-A receptor chloride channel opening in the presence of GABA. They do not, however, directly activate the GABA-A receptor in the absence of GABA. [16] This mechanism of action underscores the importance of GABAergic neurotransmission in mediating the effects of benzodiazepines.

Pharmacokinetics and Benzo Metabolism

Understanding the pharmacokinetics of benzodiazepines, particularly benzo metabolism, is paramount for predicting their duration of action, potential for drug accumulation, and interactions with other medications.

Absorption: Generally, benzodiazepines are well absorbed following oral administration from the gastrointestinal tract. An exception is clorazepate, which undergoes decarboxylation in gastric acid before absorption. Intramuscular (IM) absorption varies; diazepam and chlordiazepoxide are absorbed slowly via IM injection, while lorazepam and midazolam are absorbed more rapidly. Intravenous (IV) administration leads to quick distribution to the brain and CNS, with highly lipophilic benzodiazepines like midazolam crossing the blood-brain barrier rapidly, resulting in a fast onset of clinical effects.

Distribution: Benzodiazepines and their active metabolites exhibit high plasma protein binding. For instance, alprazolam binds approximately 70%, clonazepam 85%, and diazepam 99% to plasma proteins. The concentration of benzodiazepines in cerebrospinal fluid is roughly equivalent to the concentration of unbound drug in plasma. Diazepam is known for its rapid redistribution from the CNS to peripheral tissues, which can contribute to the termination of its clinical effect even before complete elimination.

Benzo Metabolism: Benzo metabolism is extensive and primarily occurs in the liver, involving several key pathways. This metabolic process is crucial in determining the duration of action and the formation of active metabolites, which can prolong the overall effects of the parent drug.

• Phase I Metabolism: The initial phase of benzo metabolism often involves N-desalkylation and hydroxylation, primarily mediated by cytochrome P450 enzymes (CYP450), particularly CYP3A4 and CYP2C19. This phase frequently leads to the formation of N-desalkylated metabolites that are also biologically active. Notable exceptions to this pathway include triazolam, alprazolam, and midazolam, which primarily undergo hydroxylation. For example, diazepam is metabolized to nordiazepam (desmethyldiazepam), temazepam, and oxazepam, all of which are active benzodiazepines.

• Phase II Metabolism: The second phase of benzo metabolism typically involves glucuronidation, where benzodiazepines or their phase I metabolites are conjugated with glucuronic acid. This process, catalyzed by uridine diphosphate glucuronosyltransferases (UGTs), increases water solubility, facilitating renal excretion. Lorazepam and oxazepam are examples of benzodiazepines that primarily undergo direct glucuronidation without significant CYP450 metabolism. This metabolic characteristic makes them advantageous in patients with hepatic dysfunction, as their elimination is less dependent on hepatic oxidative metabolism. [17]

• Specific Examples of Benzo Metabolism:

  • Diazepam Metabolism: As mentioned, diazepam undergoes complex benzo metabolism involving CYP enzymes, yielding active metabolites like nordiazepam, temazepam, and oxazepam. These metabolites contribute significantly to diazepam’s long duration of action.
  • Midazolam Metabolism: Midazolam is rapidly metabolized by CYP3A4, primarily to 1-hydroxymidazolam, which is also active but less potent. Due to its rapid benzo metabolism, midazolam has a shorter duration of action compared to diazepam.
  • Lorazepam and Oxazepam Metabolism: These benzodiazepines are primarily metabolized through glucuronidation, making their benzo metabolism less affected by hepatic CYP450 enzyme activity. This is a key factor in their safer use in patients with liver disease.
  • Remimazolam Metabolism: Remimazolam is unique as it is rapidly metabolized by tissue esterases to an inactive metabolite, CNS7054, resulting in a very short duration of action. [18] This distinct benzo metabolism pathway contributes to its utility in short procedural sedation.

Elimination: Benzodiazepines and their metabolites are primarily eliminated renally. The elimination half-life of benzodiazepines varies widely, influenced by factors such as age, hepatic and renal function, and the specific metabolic pathways involved. For example, diazepam, with its active metabolites, has a considerably longer half-life than midazolam. In elderly patients and those with renal dysfunction, the elimination half-life of many benzodiazepines is prolonged, potentially leading to drug accumulation and increased risk of adverse effects. [19]

Image: Simplified overview of benzo metabolism, showing Phase I CYP450 oxidation and Phase II glucuronidation pathways.

Administration of Benzodiazepines

Benzodiazepines are available in various dosage forms, including oral tablets, intravenous solutions, rectal gels, and intranasal sprays, allowing for flexible administration based on clinical needs and patient conditions.

Available Dosage Forms and Strengths

The most common routes of administration are oral and IV. However, rectal, intranasal, and IM routes are also utilized, particularly in situations where oral or IV access is challenging, such as in actively seizing patients or pediatric populations requiring rapid seizure control. Rectal administration in children is often used for seizure cessation when IV access is not readily established.

Administering benzodiazepines typically involves incremental dosing until the desired clinical effect is achieved. For IV administration, it’s important to note that achieving sufficient CNS drug concentrations may take 3 to 5 minutes. Therefore, clinicians must allow adequate time between doses to avoid over-sedation. Availability of resuscitation and airway management equipment is crucial during benzodiazepine administration, especially via the IV route, due to the risk of respiratory depression.

Adult Dosage – Examples for Common Benzodiazepines

Dosage varies significantly depending on the specific benzodiazepine, indication, and individual patient factors. Below are examples of adult dosages for commonly used benzodiazepines:

• Alprazolam: For generalized anxiety disorder, the initial dose is typically 0.25 to 0.5 mg three times daily, which can be gradually increased up to a maximum daily dose of 4 mg. For panic disorder, doses of 1 to 4 mg/day are common. Due to the potential for dependence, the lowest effective dose should always be used. [3]

• Chlordiazepoxide: For alcohol withdrawal syndrome, initial doses range from 50 to 100 mg, followed by repeated doses up to 300 mg/day as needed, guided by alcohol withdrawal assessment scales like CIWA-Ar. [21]

• Clonazepam: For panic disorder, the initial dose is 0.5 mg/day, with a maintenance dose of 1 mg/day for most patients. For seizure disorders, a starting dose of 0.5 mg three times daily is common, with a maximum recommended daily dose of 20 mg.

• Diazepam: For severe alcohol withdrawal, front-loading regimens are often used, such as 10 mg orally every hour as needed based on CIWA-Ar scores or fixed schedules like 20 mg orally every 2 hours for three doses. [12] For febrile seizures, rectal diazepam is administered at a dose of 0.5 mg/kg. [8, 22]

• Lorazepam: For convulsive status epilepticus, IV lorazepam at a dose of 0.1 mg/kg (maximum 4 mg) is recommended as an initial dose, which can be repeated after 3 to 5 minutes if needed. [10]

• Midazolam: For convulsive status epilepticus in patients without IV access, 10 mg IM midazolam is often used as a single dose. Intranasal midazolam (0.2 mg/kg, max 10 mg) is also effective in prehospital settings. [11, 23, 24]

Specific Patient Populations and Benzo Metabolism

Hepatic Impairment: Liver disease significantly impacts benzo metabolism. Benzodiazepines that undergo extensive hepatic CYP450 metabolism are more affected by liver dysfunction. Lorazepam and oxazepam, primarily metabolized by glucuronidation, are less affected and are generally considered safer choices in patients with hepatic impairment for conditions like alcohol withdrawal. Remimazolam should be used cautiously in severe hepatic impairment due to potential alterations in its rapid esterase metabolism. [25]

Renal Impairment: Renal impairment can alter benzodiazepine pharmacokinetics by reducing clearance and affecting plasma protein binding, leading to increased unbound drug concentrations. While lorazepam may be relatively safe in end-stage renal disease, diazepam accumulation is a concern. Lower starting doses and careful titration based on clinical response are crucial in patients with renal impairment. [19, 26]

Pregnancy Considerations: Most benzodiazepines are categorized as pregnancy category D, indicating potential fetal risk. Use during the first trimester should be avoided due to potential risks of congenital malformations, particularly cleft palate with diazepam and chlordiazepoxide. Some benzodiazepines, like flurazepam and temazepam (category X), are contraindicated in pregnancy due to risks of neonatal lethargy and skeletal development issues. If benzodiazepines are necessary during pregnancy for severe conditions, counseling on potential risks and neonatal withdrawal is essential. [27, 28, 29]

Breastfeeding Considerations: Benzodiazepines can be excreted in breast milk. Neonates and preterm infants are particularly susceptible to hypotensive effects, especially with concurrent opioid administration. Midazolam, lorazepam, and oxazepam are considered to have lower risk profiles and can be used cautiously if indicated, but avoidance is generally recommended unless there is a compelling indication. [30, 31, 32]

Older Patients: Older adults are more sensitive to benzodiazepines due to reduced clearance and increased receptor sensitivity. The Beers Criteria identifies benzodiazepines as potentially inappropriate medications in older adults due to increased risks of cognitive impairment, falls, and fractures. However, appropriate use may be warranted for specific indications like seizure disorders, alcohol withdrawal, or severe anxiety, using lower doses and shorter durations. [33]

Pediatric Patients: In pediatric patients, IV lorazepam and diazepam are effective for stopping prolonged seizures. Rectal diazepam, IM midazolam, and intranasal midazolam are also considered effective alternatives for acute seizure management. [10]

Image: Diagram illustrating pharmacokinetic differences among various benzodiazepines, emphasizing variations in metabolism and half-life.

Adverse Effects of Benzodiazepines

Benzodiazepine administration can lead to a range of adverse effects, primarily due to their CNS depressant properties. Common side effects include respiratory depression, drowsiness, confusion, headache, syncope, nausea, vomiting, diarrhea, and tremors.

In neonates, rare but serious adverse effects like laryngospasm and bronchospasm have been reported. Cardiovascular effects may include ventricular arrhythmias, bradycardia, or tachycardia. Gastrointestinal reactions can include retching, nausea, vomiting, and excessive salivation. CNS and neuromuscular effects may manifest as euphoria, hallucinations, ataxia, dizziness, seizure-like activity, and paresthesia. Visual disturbances, such as diplopia and blurred vision, are also possible. Long-term benzodiazepine use is associated with cognitive impairment. [34] Rare cases of cholestatic liver injury have been reported with some benzodiazepines. [35] Remimazolam use has been associated with both hypertension and hypotension, requiring blood pressure monitoring during procedures. [36]

Drug-Drug Interactions and Benzo Metabolism

Drug interactions are a significant concern with benzodiazepines, particularly those metabolized by CYP450 enzymes. Understanding benzo metabolism pathways helps predict and manage these interactions.

• CYP450 Enzyme Interactions: Benzodiazepines metabolized by CYP3A4 (e.g., alprazolam, midazolam, diazepam) can interact with drugs that are CYP3A4 inhibitors or inducers. CYP3A4 inhibitors (e.g., ketoconazole, erythromycin, ritonavir) can decrease benzo metabolism, leading to increased benzodiazepine concentrations and enhanced CNS depression. Conversely, CYP3A4 inducers (e.g., rifampin, carbamazepine, phenytoin) can accelerate benzo metabolism, potentially reducing benzodiazepine efficacy. [37, 38, 39]

• UGT Enzyme Interactions: Lorazepam and oxazepam, metabolized by UGTs, can interact with UGT inducers like carbamazepine, phenytoin, phenobarbital, and rifampin, potentially reducing their efficacy. [7]

• Opioids: Concomitant use of benzodiazepines with opioids carries a significant risk of additive CNS depression, leading to profound sedation, respiratory depression, coma, and death. This is a critical drug interaction highlighted by a boxed warning from regulatory agencies. [43]

Contraindications and Precautions

Warnings and Precautions

Contraindications for benzodiazepine use include known angle-closure glaucoma due to their potential to exacerbate this condition through muscle relaxant effects on the iris. Hypersensitivity to benzodiazepines is another contraindication; anaphylaxis and angioedema have been reported in rare cases. [40, 41] Remimazolam is specifically contraindicated in patients with hypersensitivity to dextran 40. [42]

Box Warning

The co-administration of benzodiazepines and opioids is associated with severe risks, including sedation, respiratory depression, coma, and death. This combination should be avoided unless absolutely necessary and with careful monitoring. [43]

Monitoring Benzodiazepine Therapy

Monitoring is crucial to ensure the safe and effective use of benzodiazepines. Given their CNS depressant effects, particularly on respiratory drive, continuous monitoring of vital signs, especially respiratory rate and blood pressure, is essential, particularly after IV administration. Waveform capnography can provide enhanced respiratory monitoring.

For alcohol withdrawal management, the CIWA-Ar protocol is used to assess withdrawal severity and guide benzodiazepine dosing. [21] Patients receiving parenteral lorazepam or diazepam should be monitored for hyponatremia and metabolic acidosis due to the propylene glycol content in some IV formulations. [12] In mechanically ventilated patients, sedation levels should be monitored using scales like the RASS, aiming to prevent oversedation. [23, 24, 45]

Prescription drug monitoring programs can be valuable tools in identifying potential benzodiazepine misuse. [46] Benzodiazepines are classified as DEA Schedule IV drugs, reflecting their potential for abuse and dependence.

Toxicity and Overdose Management

Signs and Symptoms of Overdose

Benzodiazepine overdose typically manifests as extreme CNS depression, including profound sedation, cognitive impairment, ataxia, and slurred speech. Respiratory depression is the most life-threatening complication, requiring immediate medical intervention. Cardiovascular effects such as hypotension and bradycardia can also occur.

Management of Overdose

Management of benzodiazepine overdose prioritizes airway, breathing, and circulation (ABCs), as per AHA guidelines. [47] Flumazenil, a GABA-A receptor antagonist, is a specific antidote that can reverse the sedative effects of benzodiazepines by competitive inhibition at the benzodiazepine binding site on the GABA-A receptor. However, flumazenil should be used cautiously as it can precipitate withdrawal seizures, especially in patients with benzodiazepine dependence or mixed overdoses. Re-sedation can occur after flumazenil wears off due to benzodiazepine redistribution.

Naloxone may be considered if opioid co-ingestion is suspected, but lower doses (e.g., 0.05 mg) are recommended initially to avoid precipitating opioid withdrawal in a sedated patient, which could lead to vomiting and aspiration. [48, 49] Activated charcoal is generally contraindicated in benzodiazepine overdose due to the risk of aspiration associated with altered mental status. [50]

Recommendations for Toxicity Management

The AHA 2023 guidelines emphasize that isolated benzodiazepine overdose rarely causes life-threatening hemodynamic instability or respiratory depression. Flumazenil can reverse benzodiazepine effects but may also trigger cardiac events, especially in mixed overdoses or with concurrent arrhythmogenic drugs or hypoxia. In mixed overdoses, naloxone may be preferred if opioid toxicity is suspected. The decision to use flumazenil should be carefully considered in the context of potential risks and benefits. [51]

Enhancing Healthcare Team Outcomes in Benzodiazepine Therapy

Effective benzodiazepine therapy requires a collaborative, interprofessional healthcare team approach. All healthcare professionals involved in prescribing, dispensing, and administering benzodiazepines must be aware of their potential benefits and risks, including adverse effects, misuse, abuse, and dependence. Pharmacists play a crucial role in medication reconciliation and identifying potential drug interactions related to benzo metabolism. Anesthesiologists and nurse anesthetists are essential in procedural sedation settings. Nurses are vital for monitoring patients, particularly in critical care settings and during alcohol withdrawal management. Neurologists and psychiatrists provide specialized expertise in using benzodiazepines for conditions like Lennox-Gastaut syndrome and benzodiazepine use disorder, respectively.

A collaborative, team-based approach, including clinical pharmacists and primary care physicians, can optimize benzodiazepine use, minimize risks, and improve patient outcomes in managing anxiety and insomnia. [54] Responsible prescribing practices, coupled with careful patient monitoring and interprofessional collaboration, are essential to maximize the therapeutic benefits of benzodiazepines while mitigating their potential harms. [52, 53]

Review Questions

(Review questions from original article can be included here)

References

(References are identical to the original article and are listed below for completeness)

1.Maust DT, Solway E, Clark SJ, Kirch M, Singer DC, Malani P. Prescription and Nonprescription Sleep Product Use Among Older Adults in the United States. Am J Geriatr Psychiatry. 2019 Jan;27(1):32-41. [PubMed: 30409547]

2.Blanco C, Han B, Jones CM, Johnson K, Compton WM. Prevalence and Correlates of Benzodiazepine Use, Misuse, and Use Disorders Among Adults in the United States. J Clin Psychiatry. 2018 Oct 16;79(6) [PMC free article: PMC10309967] [PubMed: 30403446]

3.Garakani A, Murrough JW, Freire RC, Thom RP, Larkin K, Buono FD, Iosifescu DV. Pharmacotherapy of Anxiety Disorders: Current and Emerging Treatment Options. Front Psychiatry. 2020;11:595584. [PMC free article: PMC7786299] [PubMed: 33424664]

4.March KL, Twilla JD, Reaves AB, Self TH, Slayton MM, Bergeron JB, Sakaan SA. Lorazepam versus chlordiazepoxide for the treatment of alcohol withdrawal syndrome and prevention of delirium tremens in general medicine ward patients. Alcohol. 2019 Dec;81:56-60. [PubMed: 31176787]

5.Isojarvi J, Gidal BE, Chung S, Wechsler RT. Optimizing clobazam treatment in patients with Lennox-Gastaut syndrome. Epilepsy Behav. 2018 Jan;78:149-154. [PubMed: 29202277]

6.Brigo F, Igwe SC, Bragazzi NL, Lattanzi S. Clonazepam monotherapy for treating people with newly diagnosed epilepsy. Cochrane Database Syst Rev. 2019 Nov 19;2019(11) [PMC free article: PMC6863099] [PubMed: 31742671]

7.Riss J, Cloyd J, Gates J, Collins S. Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurol Scand. 2008 Aug;118(2):69-86. [PubMed: 18384456]

8.Chiang LM, Wang HS, Shen HH, Deng ST, Tseng CH, Chen YI, Chou ML, Hung PC, Lin KL. Rectal diazepam solution is as good as rectal administration of intravenous diazepam in the first-aid cessation of seizures in children with intractable epilepsy. Pediatr Neonatol. 2011 Feb;52(1):30-3. [PubMed: 21385654]

9.Sateia MJ, Buysse DJ, Krystal AD, Neubauer DN, Heald JL. Clinical Practice Guideline for the Pharmacologic Treatment of Chronic Insomnia in Adults: An American Academy of Sleep Medicine Clinical Practice Guideline. J Clin Sleep Med. 2017 Feb 15;13(2):307-349. [PMC free article: PMC5263087] [PubMed: 27998379]

10.Glauser T, Shinnar S, Gloss D, Alldredge B, Arya R, Bainbridge J, Bare M, Bleck T, Dodson WE, Garrity L, Jagoda A, Lowenstein D, Pellock J, Riviello J, Sloan E, Treiman DM. Evidence-Based Guideline: Treatment of Convulsive Status Epilepticus in Children and Adults: Report of the Guideline Committee of the American Epilepsy Society. Epilepsy Curr. 2016 Jan-Feb;16(1):48-61. [PMC free article: PMC4749120] [PubMed: 26900382]

11.Devlin JW, Skrobik Y, Gélinas C, Needham DM, Slooter AJC, Pandharipande PP, Watson PL, Weinhouse GL, Nunnally ME, Rochwerg B, Balas MC, van den Boogaard M, Bosma KJ, Brummel NE, Chanques G, Denehy L, Drouot X, Fraser GL, Harris JE, Joffe AM, Kho ME, Kress JP, Lanphere JA, McKinley S, Neufeld KJ, Pisani MA, Payen JF, Pun BT, Puntillo KA, Riker RR, Robinson BRH, Shehabi Y, Szumita PM, Winkelman C, Centofanti JE, Price C, Nikayin S, Misak CJ, Flood PD, Kiedrowski K, Alhazzani W. Clinical Practice Guidelines for the Prevention and Management of Pain, Agitation/Sedation, Delirium, Immobility, and Sleep Disruption in Adult Patients in the ICU. Crit Care Med. 2018 Sep;46(9):e825-e873. [PubMed: 30113379]

12.The ASAM Clinical Practice Guideline on Alcohol Withdrawal Management. J Addict Med. 2020 May/Jun;14(3S Suppl 1):1-72. [PubMed: 32511109]

13.Qaseem A, Kansagara D, Forciea MA, Cooke M, Denberg TD., Clinical Guidelines Committee of the American College of Physicians. Management of Chronic Insomnia Disorder in Adults: A Clinical Practice Guideline From the American College of Physicians. Ann Intern Med. 2016 Jul 19;165(2):125-33. [PubMed: 27136449]

14.Kilpatrick GJ. Remimazolam: Non-Clinical and Clinical Profile of a New Sedative/Anesthetic Agent. Front Pharmacol. 2021;12:690875. [PMC free article: PMC8329483] [PubMed: 34354587]

15.Poisbeau P, Gazzo G, Calvel L. Anxiolytics targeting GABAA receptors: Insights on etifoxine. World J Biol Psychiatry. 2018;19(sup1):S36-S45. [PubMed: 30204559]

16.Sigel E, Steinmann ME. Structure, function, and modulation of GABA(A) receptors. J Biol Chem. 2012 Nov 23;287(48):40224-31. [PMC free article: PMC3504738] [PubMed: 23038269]

17.Griffin CE, Kaye AM, Bueno FR, Kaye AD. Benzodiazepine pharmacology and central nervous system-mediated effects. Ochsner J. 2013 Summer;13(2):214-23. [PMC free article: PMC3684331] [PubMed: 23789008]

18.Sneyd JR, Rigby-Jones AE. Remimazolam for anaesthesia or sedation. Curr Opin Anaesthesiol. 2020 Aug;33(4):506-511. [PubMed: 32530890]

19.Wilcock A, Charlesworth S, Twycross R, Waddington A, Worthington O, Murtagh FEM, Beavis J, King S, Mihalyo M, Kotlinska-Lemieszek A. Prescribing Non-Opioid Drugs in End-Stage Kidney Disease. J Pain Symptom Manage. 2017 Nov;54(5):776-787. [PubMed: 28843456]

20.Borrelli EP, Bratberg J, Hallowell BD, Greaney ML, Kogut SJ. Application of a diazepam milligram equivalency algorithm to assess benzodiazepine dose intensity in Rhode Island in 2018. J Manag Care Spec Pharm. 2022 Jan;28(1):58-68. [PMC free article: PMC10373022] [PubMed: 34949119]

21.Melkonian A, Patel R, Magh A, Ferm S, Hwang C. Assessment of a Hospital-Wide CIWA-Ar Protocol for Management of Alcohol Withdrawal Syndrome. Mayo Clin Proc Innov Qual Outcomes. 2019 Sep;3(3):344-349. [PMC free article: PMC6713876] [PubMed: 31485573]

22.Ghazavi M, Nasiri J, Yaghini O, Soltani R. Oral Diazepam in Febrile Seizures Following Acellular Pertussis Vaccination. Adv Biomed Res. 2019;8:29. [PMC free article: PMC6507365] [PubMed: 31114769]

23.Kress JP, Pohlman AS, O’Connor MF, Hall JB. Daily interruption of sedative infusions in critically ill patients undergoing mechanical ventilation. N Engl J Med. 2000 May 18;342(20):1471-7. [PubMed: 10816184]

24.Hughes CG, Mailloux PT, Devlin JW, Swan JT, Sanders RD, Anzueto A, Jackson JC, Hoskins AS, Pun BT, Orun OM, Raman R, Stollings JL, Kiehl AL, Duprey MS, Bui LN, O’Neal HR, Snyder A, Gropper MA, Guntupalli KK, Stashenko GJ, Patel MB, Brummel NE, Girard TD, Dittus RS, Bernard GR, Ely EW, Pandharipande PP., MENDS2 Study Investigators. Dexmedetomidine or Propofol for Sedation in Mechanically Ventilated Adults with Sepsis. N Engl J Med. 2021 Apr 15;384(15):1424-1436. [PMC free article: PMC8162695] [PubMed: 33528922]

25.Gershkovich P, Wasan KM, Ribeyre C, Ibrahim F, McNeill JH. Effect of variations in treatment regimen and liver cirrhosis on exposure to benzodiazepines during treatment of alcohol withdrawal syndrome. Drugs Context. 2015;4:212287. [PMC free article: PMC4544271] [PubMed: 26322116]

26.Wyne A, Rai R, Cuerden M, Clark WF, Suri RS. Opioid and benzodiazepine use in end-stage renal disease: a systematic review. Clin J Am Soc Nephrol. 2011 Feb;6(2):326-33. [PMC free article: PMC3052223] [PubMed: 21071517]

27.Creeley CE, Denton LK. Use of Prescribed Psychotropics during Pregnancy: A Systematic Review of Pregnancy, Neonatal, and Childhood Outcomes. Brain Sci. 2019 Sep 14;9(9) [PMC free article: PMC6770670] [PubMed: 31540060]

28.Antenatal and postnatal mental health: clinical management and service guidance. National Institute for Health and Care Excellence (NICE); London: Apr, 2018. [PubMed: 31990493]

29.Shyken JM, Babbar S, Babbar S, Forinash A. Benzodiazepines in Pregnancy. Clin Obstet Gynecol. 2019 Mar;62(1):156-167. [PubMed: 30628916]

30.Drugs and Lactation Database (LactMed®) [Internet]. National Institute of Child Health and Human Development; Bethesda (MD): Jan 15, 2024. Lorazepam. [PubMed: 30000290]

31.Drugs and Lactation Database (LactMed®) [Internet]. National Institute of Child Health and Human Development; Bethesda (MD): Oct 15, 2024. Midazolam. [PubMed: 30000294]

32.Uguz F. A New Safety Scoring System for the Use of Psychotropic Drugs During Lactation. 2021 Jan-Feb 01Am J Ther. 28(1):e118-e126. [PubMed: 30601177]

33.By the 2023 American Geriatrics Society Beers Criteria® Update Expert Panel. American Geriatrics Society 2023 updated AGS Beers Criteria® for potentially inappropriate medication use in older adults. J Am Geriatr Soc. 2023 Jul;71(7):2052-2081. [PubMed: 37139824]

34.Crowe SF, Stranks EK. The Residual Medium and Long-term Cognitive Effects of Benzodiazepine Use: An Updated Meta-analysis. Arch Clin Neuropsychol. 2018 Nov 01;33(7):901-911. [PubMed: 29244060]

35.LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. National Institute of Diabetes and Digestive and Kidney Diseases; Bethesda (MD): Jan 24, 2017. Benzodiazepines. [PMC free article: PMC547852] [PubMed: 31643621]

36.Lee A, Shirley M. Remimazolam: A Review in Procedural Sedation. Drugs. 2021 Jul;81(10):1193-1201. [PubMed: 34196946]

37.Weaver MF. Prescription Sedative Misuse and Abuse. Yale J Biol Med. 2015 Sep;88(3):247-56. [PMC free article: PMC4553644] [PubMed: 26339207]

38.Boulenc X, Nicolas O, Hermabessière S, Zobouyan I, Martin V, Donazzolo Y, Ollier C. CYP3A4-based drug-drug interaction: CYP3A4 substrates’ pharmacokinetic properties and ketoconazole dose regimen effect. Eur J Drug Metab Pharmacokinet. 2016 Feb;41(1):45-54. [PubMed: 25374256]

39.Dresser GK, Spence JD, Bailey DG. Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition. Clin Pharmacokinet. 2000 Jan;38(1):41-57. [PubMed: 10668858]

40.Park MY, Kim WJ, Lee E, Kim C, Son SJ, Yoon JS, Kim W, Namkoong K. Association between use of benzodiazepines and occurrence of acute angle-closure glaucoma in the elderly: A population-based study. J Psychosom Res. 2019 Jul;122:1-5. [PubMed: 31126405]

41.Haybarger E, Young AS, Giovannitti JA. Benzodiazepine Allergy With Anesthesia Administration: A Review of Current Literature. Anesth Prog. 2016 Fall;63(3):160-7. [PMC free article: PMC5011959] [PubMed: 27585420]

42.Shiratori T, Sato A, Fukuzawa M, Kondo N, Tanno S. Severe Dextran-Induced Anaphylactic Shock during Induction of Hypertension-Hypervolemia-Hemodilution Therapy following Subarachnoid Hemorrhage. Case Rep Crit Care. 2015;2015:967560. [PMC free article: PMC4480245] [PubMed: 26171255]

43.Aschenbrenner DS. Stronger Boxed Warning for Benzodiazepines. Am J Nurs. 2021 Mar 01;121(3):22-23. [PubMed: 33625005]

44.Hatlestad D. Capnography in sedation and pain management. Emerg Med Serv. 2005 Mar;34(3):65-9. [PubMed: 15839539]

45.Medlej K. Calculated decisions: Richmond Agitation-Sedation Scale (RASS). Emerg Med Pract. 2021 Mar 15;23(Suppl 3):CD3-CD4. [PubMed: 33729737]

46.Liang D, Guo H, Shi Y. Mandatory use of prescription drug monitoring program and benzodiazepine prescribing among U.S. Medicaid enrollees. Subst Abus. 2021;42(3):294-301. [PMC free article: PMC7202951] [PubMed: 31697195]

47.Panchal AR, Bartos JA, Cabañas JG, Donnino MW, Drennan IR, Hirsch KG, Kudenchuk PJ, Kurz MC, Lavonas EJ, Morley PT, O’Neil BJ, Peberdy MA, Rittenberger JC, Rodriguez AJ, Sawyer KN, Berg KM., Adult Basic and Advanced Life Support Writing Group. Part 3: Adult Basic and Advanced Life Support: 2020 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. Circulation. 2020 Oct 20;142(16_suppl_2):S366-S468. [PubMed: 33081529]

48.Gallo AT, Hulse G. Pharmacological uses of flumazenil in benzodiazepine use disorders: a systematic review of limited data. J Psychopharmacol. 2021 Mar;35(3):211-220. [PubMed: 33426982]

49.Sivilotti ML. Flumazenil, naloxone and the ‘coma cocktail’. Br J Clin Pharmacol. 2016 Mar;81(3):428-36. [PMC free article: PMC4767210] [PubMed: 26469689]

50.Zellner T, Prasa D, Färber E, Hoffmann-Walbeck P, Genser D, Eyer F. The Use of Activated Charcoal to Treat Intoxications. Dtsch Arztebl Int. 2019 May 03;116(18):311-317. [PMC free article: PMC6620762] [PubMed: 31219028]

51.Lavonas EJ, Akpunonu PD, Arens AM, Babu KM, Cao D, Hoffman RS, Hoyte CO, Mazer-Amirshahi ME, Stolbach A, St-Onge M, Thompson TM, Wang GS, Hoover AV, Drennan IR., American Heart Association. 2023 American Heart Association Focused Update on the Management of Patients With Cardiac Arrest or Life-Threatening Toxicity Due to Poisoning: An Update to the American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. Circulation. 2023 Oct 17;148(16):e149-e184. [PubMed: 37721023]

52.Jørgensen MB, Osler M. Should benzodiazepines be avoided? Acta Psychiatr Scand. 2018 Aug;138(2):89-90. [PubMed: 30398297]

53.Revet A, Yrondi A, Montastruc F. [Good practices in prescribing benzodiazepines]. Presse Med. 2018 Oct;47(10):872-877. [PubMed: 30385184]

54.Furbish SML, Kroehl ME, Loeb DF, Lam HM, Lewis CL, Nelson J, Chow Z, Trinkley KE. A Pharmacist-Physician Collaboration to Optimize Benzodiazepine Use for Anxiety and Sleep Symptom Control in Primary Care. J Pharm Pract. 2017 Aug;30(4):425-433. [PMC free article: PMC5511764] [PubMed: 27480874]

Disclosure: Connor Bounds declares no relevant financial relationships with ineligible companies.

Disclosure: Preeti Patel declares no relevant financial relationships with ineligible companies.